Yüklüyor......
Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
PURPOSE: Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolon...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Clinical Oncology
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3083867/ https://ncbi.nlm.nih.gov/pubmed/21321298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.6455 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|